{"id":31528,"date":"2025-04-10T14:02:33","date_gmt":"2025-04-10T06:02:33","guid":{"rendered":"https:\/\/flcube.com\/?p=31528"},"modified":"2025-04-10T14:02:34","modified_gmt":"2025-04-10T06:02:34","slug":"sino-biopharmas-tqb3019-gains-nmpa-approval-for-hematological-malignancies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31528","title":{"rendered":"Sino Biopharma’s TQB3019 Gains NMPA Approval for Hematological Malignancies"},"content":{"rendered":"\n

China-based Sino Biopharmaceutical Ltd (HKG: 1177<\/a>) announced that it has received clinical approval from the National Medical Products Administration (NMPA) for its investigational BTK-targeted PROTAC drug, TQB3019, for the treatment of hematological malignancies. This marks a significant milestone in the development of innovative therapies for blood cancers.<\/p>\n\n\n\n

Drug Mechanism<\/strong>
TQB3019 is a novel PROTAC drug designed to bind to the BTK protein and E3 ubiquitin ligase, activating the ubiquitin proteasome pathway to degrade target proteins. This mechanism effectively inhibits BTK and downstream signaling, suppressing tumor growth. Preclinical studies have demonstrated significant therapeutic effects, clear mechanisms of action, and good safety, positioning TQB3019 as a promising solution to overcome resistance to traditional BTK inhibitors.<\/p>\n\n\n\n

Global Innovation<\/strong>
TQB3019 stands out as the first product of its kind globally, highlighting Sino Biopharma’s commitment to advancing cutting-edge treatments for hematological malignancies. The approval underscores the company’s leadership in the field of protein degradation therapies.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received clinical approval from the…<\/p>\n","protected":false},"author":1,"featured_media":31530,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,908,313,70],"class_list":["post-31528","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-hkg-1177","tag-sino-biopharmaceutical","tag-tpd"],"yoast_head":"\nSino Biopharma's TQB3019 Gains NMPA Approval for Hematological Malignancies - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received clinical approval from the National Medical Products Administration (NMPA) for its investigational BTK-targeted PROTAC drug, TQB3019, for the treatment of hematological malignancies. This marks a significant milestone in the development of innovative therapies for blood cancers.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31528\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharma's TQB3019 Gains NMPA Approval for Hematological Malignancies\" \/>\n<meta property=\"og:description\" content=\"China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received clinical approval from the National Medical Products Administration (NMPA) for its investigational BTK-targeted PROTAC drug, TQB3019, for the treatment of hematological malignancies. This marks a significant milestone in the development of innovative therapies for blood cancers.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31528\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-10T06:02:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-10T06:02:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1005-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31528#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31528\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharma’s TQB3019 Gains NMPA Approval for Hematological Malignancies\",\"datePublished\":\"2025-04-10T06:02:33+00:00\",\"dateModified\":\"2025-04-10T06:02:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31528\"},\"wordCount\":165,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31528#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1005-png.webp\",\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"HKG: 1177\",\"Sino Biopharmaceutical\",\"TPD\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31528#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31528\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31528\",\"name\":\"Sino Biopharma's TQB3019 Gains NMPA Approval for Hematological Malignancies - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31528#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31528#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1005-png.webp\",\"datePublished\":\"2025-04-10T06:02:33+00:00\",\"dateModified\":\"2025-04-10T06:02:34+00:00\",\"description\":\"China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received clinical approval from the National Medical Products Administration (NMPA) for its investigational BTK-targeted PROTAC drug, TQB3019, for the treatment of hematological malignancies. This marks a significant milestone in the development of innovative therapies for blood cancers.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31528#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31528\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31528#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1005-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1005-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sino Biopharma's TQB3019 Gains NMPA Approval for Hematological Malignancies\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31528#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharma’s TQB3019 Gains NMPA Approval for Hematological Malignancies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharma's TQB3019 Gains NMPA Approval for Hematological Malignancies - Insight, China's Pharmaceutical Industry","description":"China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received clinical approval from the National Medical Products Administration (NMPA) for its investigational BTK-targeted PROTAC drug, TQB3019, for the treatment of hematological malignancies. This marks a significant milestone in the development of innovative therapies for blood cancers.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31528","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharma's TQB3019 Gains NMPA Approval for Hematological Malignancies","og_description":"China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received clinical approval from the National Medical Products Administration (NMPA) for its investigational BTK-targeted PROTAC drug, TQB3019, for the treatment of hematological malignancies. This marks a significant milestone in the development of innovative therapies for blood cancers.","og_url":"https:\/\/flcube.com\/?p=31528","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-10T06:02:33+00:00","article_modified_time":"2025-04-10T06:02:34+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1005-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31528#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31528"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharma’s TQB3019 Gains NMPA Approval for Hematological Malignancies","datePublished":"2025-04-10T06:02:33+00:00","dateModified":"2025-04-10T06:02:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31528"},"wordCount":165,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31528#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1005-png.webp","keywords":["Cancer","Clinical trial approval \/ initiation","HKG: 1177","Sino Biopharmaceutical","TPD"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31528#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31528","url":"https:\/\/flcube.com\/?p=31528","name":"Sino Biopharma's TQB3019 Gains NMPA Approval for Hematological Malignancies - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31528#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31528#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1005-png.webp","datePublished":"2025-04-10T06:02:33+00:00","dateModified":"2025-04-10T06:02:34+00:00","description":"China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received clinical approval from the National Medical Products Administration (NMPA) for its investigational BTK-targeted PROTAC drug, TQB3019, for the treatment of hematological malignancies. This marks a significant milestone in the development of innovative therapies for blood cancers.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31528#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31528"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31528#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1005-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1005-png.webp","width":1080,"height":608,"caption":"Sino Biopharma's TQB3019 Gains NMPA Approval for Hematological Malignancies"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31528#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharma’s TQB3019 Gains NMPA Approval for Hematological Malignancies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1005-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31528","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31528"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31528\/revisions"}],"predecessor-version":[{"id":31531,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31528\/revisions\/31531"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31530"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31528"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31528"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}